Adamas Pharmaceuticals (ADMS) Misses Q3 EPS by 13c

Adamas Pharmaceuticals (NASDAQ: ADMS) reported Q3 EPS of ($0.57), $0.13 worse than the analyst estimate of ($0.44).

For earnings history and earnings-related data on Adamas Pharmaceuticals (ADMS) click here.

You May Also Be Interested In

• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
• AXIL Brands (AXIL) Tops Q4 EPS by 4c
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance